Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Pharmacogenomics response

Pharmacogenomic Response to a Multifactorial Treatment in Alzheimer Disease... [Pg.305]

Fig. 10.15 Pharmacogenomic response to a multifactorial therapy in Alzheimer s disease (AD) according to a trigenic cluster integrated by the apolipoprotein E (APOE), presenUin 1 (PSl), and presenilin 2 (PS2) genes. (Adapted from refs. 13 0, and 291.)... Fig. 10.15 Pharmacogenomic response to a multifactorial therapy in Alzheimer s disease (AD) according to a trigenic cluster integrated by the apolipoprotein E (APOE), presenUin 1 (PSl), and presenilin 2 (PS2) genes. (Adapted from refs. 13 0, and 291.)...
Boni IP, Leister C, Bender G Fitzpatrick V, Twine N, Stover J, Domer A, Immermann F, Burczynski ME. (2005) Population pharmacokinetics of CCI-779 Correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin Pharmacol Ther 77 76-89. [Pg.142]

Discovery of new diagnostic and prognostic indicators and biomarkers of therapeutic response, and prediction of patients most likely to benefit from the diug and use in general pharmacogenomic studies (Fig. 2)... [Pg.528]

Evans WE, Johnson JA Pharmacogenomics the inherited basis for interindividual differences in drug response. Anna Rev Genomics Hum Genet 2001 2 9. [Pg.632]

Pharmacogenomics The science of understanding the correlation between an individual patient s genetic make-up (genotype) and their response to drug treatment. [Pg.1573]

Xing, Q. et al. (2006b). Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics, 7, 987-93. [Pg.61]

Lee, H.-J., Cha, J.-H., Ham, B.-J. etal. (2004). Association between a G-protein boldbeta3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders. Pharmacogenomics J., 4, 29-33. [Pg.167]

Lerman, C.W.E., Patterson, F., Rukstalis, M., Audrain-McGovem, J., Restine, S., Shields, P.G., Kaufmann, V., Redden, D., Benowitz, N., Berrettine, W.H. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J. 4 184, 2004. [Pg.50]

Drazen JM, Yandava CN, Dube L, SzCZERBACK N, HlPPENSTEEL R, PlLLARI et al. Pharmacogenomic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nature Genet 1999 22 168-170. [Pg.55]

Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M et al. Pharmacogenomic prediction of clozapine response. Lancet 2000 355 1615— 1616. [Pg.57]


See other pages where Pharmacogenomics response is mentioned: [Pg.305]    [Pg.471]    [Pg.183]    [Pg.183]    [Pg.305]    [Pg.471]    [Pg.183]    [Pg.183]    [Pg.769]    [Pg.951]    [Pg.953]    [Pg.954]    [Pg.51]    [Pg.53]    [Pg.81]    [Pg.163]    [Pg.165]    [Pg.811]    [Pg.35]    [Pg.5]    [Pg.6]    [Pg.7]    [Pg.8]    [Pg.22]    [Pg.29]    [Pg.37]    [Pg.38]    [Pg.38]    [Pg.39]    [Pg.42]    [Pg.45]    [Pg.46]    [Pg.46]    [Pg.48]    [Pg.49]    [Pg.54]    [Pg.58]    [Pg.59]    [Pg.75]    [Pg.75]    [Pg.76]    [Pg.77]    [Pg.77]   
See also in sourсe #XX -- [ Pg.16 , Pg.17 ]




SEARCH



Pharmacogenomic

Pharmacogenomics

© 2024 chempedia.info